ФААС МАКНАЙТ Сьюзан (US),КОФИЛЛ Роксанне (US),ЯН Ян (US)
申请号：
RU2012134369/15
公开号：
RU2012134369A
申请日:
2011.01.11
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating cancer, comprising administering to a patient in need thereof an anti-CD200 antibody or antigen binding fragment thereof in an amount and frequency that are sufficient to treat cancer, the patient being infected with cancer and having an immune system capable of establishing an immune response against cancer. . The method of claim 1, wherein (a) for less than two months before administration of the anti-CD200 antibody or antigen binding fragment thereof, the patient was not given a chemotherapeutic agent or immunosuppressive agent, or (b) the patient is not infected with HIV. The method of claim 1, wherein the cancer is chronic lymphocytic leukemia (CLL). The method of claim 1, wherein the cancer is a solid tumor. The method of claim 4, wherein the solid tumor is colon cancer, breast cancer, lung cancer, kidney cancer, pancreatic cancer, thyroid cancer, skin cancer, nervous system cancer, cervical cancer, ovarian cancer, testicular cancer, head and neck cancer, eye cancer, stomach cancer, or liver cancer. 6. The method of claim 5, wherein the nervous system cancer is a neuroblastoma. The method of claim 1, wherein, at each dose, the amount of anti-CD200 antibody or antigen binding fragment thereof administered to a patient is at least (i) 100 mg / MP； (ii) 200 mg / mpacient； or (iii) 400 mg / mpacient. 8. The method of claim 1, wherein the anti-CD200 antibody or antigen binding fragment thereof is administered to the patient at least once every two weeks. The method of claim 1, wherein the anti-CD200 antibody is a mouse antibody, a chimeric antibody, a humanized antibody, or a human antibody. The method according to claim 1, wherein the antigen binding fragment is selected from the group consisting of Fab, F (ab '), Fv, and single chain a1. Способ лечения рака, включающий введение нуждающемуся в этом пациенту антитела против CD200 или его антигенсвязывающего фрагмента в количестве и с частотой, которые являются достаточными для лечения рака,
